| Products | Business Development | News | Contact |
 |
||
Advisory Board
Sir Gregory Winter (Chairman)
MRC Laboratory of Molecular Biology, Cambridge, UK
Sir Ravinder Maini
Imperial College, London, UK
Anthony Rees
MIP Technologies AB, Lund, Sweden
Florian Rüker
University of Natural Resources and Applied Life Sciences Vienna, Austria
Professor Sir Gregory Winter, CBE, FRS, FMedSci, HonFRCP
MRC Laboratory of Molecular Biology, Cambridge, UK
Sir Gregory Winter is Deputy Director of the Medical Research Council's Laboratory of Molecular Biology (LMB) and Head of the Division of Protein and Nucleic Acids Chemistry, succeeding Cesar Milstein as joint Head in 1994. He co-founded the MRC Centre for Protein Engineering with Alan Fersht and is now the Deputy Director.
He is one of the pioneers of protein engineering. In particular he developed technologies for making humanised antibodies (by grafting hypervariable regions from rodent antibodies to human antibodies) and also for making human antibodies in bacteria (by use of antibody repertories and phage display technologies). Most of the therapeutic antibodies on the market were developed using methods devised by him.
He was a Founder and Director of Cambridge Antibody Technology, now part of Medimmune, Astra Zeneca's biologics business unit. In 2000 he co-founded Domantis and acted as Director and Chairman of the Scientific Advisory Board. In 2006, Domantis was acquired by GSK and is now part of GSK's Biopharmaceuticals Centre of Excellence for Drug Discovery.
Sir Gregory has received numerous international prizes and awards, and in 2004 was knighted for services to science.
Professor Sir Ravinder Maini, FRCP, FMedSci, FRS
Imperial College, London, UK
Sir Ravinder Maini is Emeritus Professor of Rheumatology at Imperial College, University of London, UK, previously Scientific Director and currently currently a member of the Trust Board of The Kennedy Institute of Rheumatology, London.
Sir Ravinder has a long and distinguished medical career with research interests encompassing immunotherapy, production and measurement of autoantibodes and pathogenesis of immune inflammatory rheumatic diseases. He is a pioneer in the research and development of anti-TNF therapy which has become established as an important option in the treatment of rheumatoid arthritis and other immune-inflammatory diseases such as Crohn's disease, ankylosing spondylitis, psoriatic arthritis and psoriasis and has spawned a billion dollar industry for anti-TNF biologicals.
He played a vital role in research and clinical development of top-selling anti-inflammatory drug Remicade and was a non-Executive Director of Domantis, an antibody engineering company founded in 2000 by Sir Gregory Winter and Ian Tomlinson and acquired by GSK in 2006.
Sir Ravinder is a Fellow of the Academy of Medical Sciences and the Royal Society, was knighted in 2003 and is a co-recipient of the Crafoord Prize from the Swedish Academy of Sciences in 2000 and the Albert Lasker Clinical Medical Research Award (USA) in 2003. He is member of a number of prestigious international societies, committees and clubs, co-edits Arthritis Research and Therapy and has published over 400 articles in refereed journals and invited reviews.
Professor Anthony Rees
MIP Technologies AB
Anthony Rees is CEO of Technologies AB, a company developing molecularly imprinted polymers. He was previously Scientific Director at the French Biotech company Synt:em and before that Head of the School of Biology & Biochemistry at the University of Bath, UK. He was on the Faculty of Oxford University from 1980-1990 from where he obtained his doctorate.
Dr. Rees is a pioneer in antibody engineering and modeling, in 1989 was scientific co-founder of Oxford Molecular plc which marketed the AbM software package developed by his group at Universities of Oxford & Bath. He also developed WAM - Web Antibody Modelling - which is widely used in antibody engineering and allows to construct 3D models of antibody Fv sequences on-line using a combination of established theoretical methods together with antibody structural information.
Professor Florian Rüker
Associate Professor, University of Natural Resources and Applied Life Sciences Vienna,
Austria
Florian Rüker received his doctorate from the University of Natural Resources and Applied Life Sciences, Vienna, where he has been leading a research group working in the field of protein structural biology, engineering and expression for the past 21 years, with a focus on antibodies and serum albumin. For several years, he has also been active as a project leader for New Century Pharmaceuticals Inc. (Huntsville, AL). At present, he is an associate Professor at the Department of Biotechnology at the University of Natural Resources and Applied Life Sciences, Vienna, Austria.